Detailed view for LmjF.30.0250

Basic information

TDR Targets ID: 22274
Leishmania major, ubiquitin hydrolase, putative,cysteine peptidase, Clan CA, family C19, putative
Source Database / ID:  TriTrypDB  GeneDB

pI: 5.0257 | Length (AA): 1131 | MW (Da): 126167 | Paralog Number: 0

Signal peptide: N | GPI Anchor: N | Predicted trans-membrane segments: 0

Druggability Group : DG1

Targets have been classified into druggability groups (DG) according to their druggability score in network driven prioritizations. DGs range from 1 to 5; the higher the group number, the higher the chance of the target to be druggable

Pfam domains

PF00929   Exonuclease
PF13423   Ubiquitin carboxyl-terminal hydrolase

Gene Ontology

Mouse over links to read term descriptions.
GO:0005622   intracellular  
GO:0003676   nucleic acid binding  
GO:0005515   protein binding  
GO:0004527   exonuclease activity  

Metabolic Pathways

RNA degradation (KEGG)

Structural information

Modbase 3D models:

There are 9 models calculated for this protein. More info on these models, including the models themselves is available at: Modbase

Target Beg Target End Template Template Beg Template End Identity Evalue Model Score MPQS zDope
4 321 1erj (A) 326 709 14.00 0 1 0.09 -0.32
7 317 1got (B) 41 339 12.00 0 0.83 0.46 -0.63
844 1030 1wlj (A) 6 174 29.00 0 1 0.36 -0.29
1 55 4cy3 (A) 172 232 22.00 0.47 0.36 0.21203 -0.27
259 373 3bdn (A) 136 235 35.00 0.12 0.8 0.24298 0.87
486 615 5l8h (A) 32 140 30.00 0.38 0.97 0.289243 -0.39
490 1041 4czw (A) 495 1093 31.00 0 1 0.650364 0.46
675 1025 4xr7 (G) 720 1086 36.00 0 1 0.457645 1.31
675 1050 4q8h (A) 720 1111 35.00 0 1 0.529749 1.01

Help me make sense of these data.

Target Beg: first modeled residue
Target End: last modeled residue
Template: template structure used for modelling (PDB accession and chain)
Template Beg: first template residue in target-template alignment
Template End: last template residue in target-template alignment
Identity: sequence identity
Evalue: E value for target-template hit
Model Score: GA341 score (>0.7 for reliable model)
MPQS: ModPipe Quality Score (>1.1 for reliable model)
zDope: zDope Score (negative for reliable model)

A more detailed description of these scores is available at the Modbase Model Evaluation Help Pages, and in the papers referenced therein.

PDB Structures:

No structure availble in the PDB for this protein

Expression

Upregulation Percent Ranking Stage Dataset
Upper 60-80% percentile metacyclic. Fernandes MC
Upregulation Percent Ranking Stage Dataset
Mid 40-60% percentile amastigotes. Fernandes MC
Show/Hide expression data references
  • Fernandes MC Dual Transcriptome Profiling of Leishmania-Infected Human Macrophages Reveals Distinct Reprogramming Signatures.

Orthologs

Ortholog group members (OG5_128883)

Species Accession Gene Product
Babesia bovis BBOV_III004920   exonuclease family protein
Brugia malayi Bm1_20810   CG8232-PA
Candida albicans CaO19.4764   Component of Pab1p-stimulated poly(A) ribonuclease
Candida albicans CaO19.12228   Component of Pab1p-stimulated poly(A) ribonuclease
Caenorhabditis elegans CELE_F31E3.4   Protein PANL-2
Dictyostelium discoideum DDB_G0269694   WD40-like domain-containing protein
Drosophila melanogaster Dmel_CG8232   PAN2 ortholog (S. cerevisiae)
Echinococcus granulosus EgrG_000610700   PAB dependent polyA specific ribonuclease
Echinococcus multilocularis EmuJ_000610700   PAB dependent poly(A) specific ribonuclease
Homo sapiens ENSG00000135473   PAN2 poly(A) specific ribonuclease subunit
Leishmania braziliensis LbrM.30.0260   ubiquitin hydrolase, putative,cysteine peptidase, Clan CA, family C19, putative
Leishmania donovani LdBPK_300250.1   ubiquitin hydrolase, putative
Leishmania infantum LinJ.30.0250   ubiquitin hydrolase, putative,cysteine peptidase, Clan CA, family C19, putative
Leishmania major LmjF.30.0250   ubiquitin hydrolase, putative,cysteine peptidase, Clan CA, family C19, putative
Leishmania mexicana LmxM.29.0250   ubiquitin hydrolase, putative,cysteine peptidase, Clan CA, family C19, putative
Loa Loa (eye worm) LOAG_00636   hypothetical protein
Mus musculus ENSMUSG00000005682   PAN2 polyA specific ribonuclease subunit homolog (S. cerevisiae)
Neospora caninum NCLIV_032340   PAB-dependent poly(A)-specific ribonuclease subunit PAN2, related
Saccharomyces cerevisiae YGL094C   Pan2p
Schistosoma japonicum Sjp_0001560   ko:K01072 ubiquitin thiolesterase [EC3.1.2.15], putative
Schistosoma mansoni Smp_130800   ubiquitin specific protease 52 / poly(A) ribonuclease subunit pan2
Schmidtea mediterranea mk4.004150.00  
Trypanosoma brucei gambiense Tbg972.6.1360   ubiquitin hydrolase, putative
Trypanosoma brucei Tb11.v5.0553   ubiquitin hydrolase, putative
Trypanosoma congolense TcIL3000_6_1240   ubiquitin hydrolase, putative
Trypanosoma cruzi TcCLB.507017.120   ubiquitin hydrolase, putative
Trypanosoma cruzi TcCLB.505807.270   ubiquitin hydrolase, putative
Toxoplasma gondii TGME49_232360   exonuclease
Theileria parva TP02_0456   hypothetical protein

Essentiality

LmjF.30.0250 has one or more orthologs with essentiality data
Gene/Ortholog Organism Phenotype Source Study
TGME49_232360 Toxoplasma gondii Essentiality uncertain sidik
Show/Hide essentiality data references
  • blattner Systematic mutagenesis of the E. coli (MG1655) genome J Bacteriol 2004, 186:4921-4930
  • plasmo Functional Profiling of a Plasmodium Genome Reveals an Abundance of Essential Genes. Bushell, Ellen, et al. "Functional profiling of a Plasmodium genome reveals an abundance of essential genes." Cell 170.2 (2017): 260-272.
  • shigen Profiling of E. coli Chromosome (PEC) National Institute of Genetics, Japan
  • neb C. elegans RNAi phenotypes Data obtained from Wormbase WS150, curated by K. Chaudary and T. Carlow, New England Biolabs
  • wormbase C. elegans RNAi experiments WormBase web site, http://www.wormbase.org, release WS170
  • keio Systematic single-gene knock-out mutants of E. coli K12 The Keio Collection
  • gerdes Experimental determination and system-level analysis of essential genes in E. coli MG1655 Gerdes et al., J Bacteriol. 2003 185:5673-84
  • nmpdr Genome-scale essentiality datasets from published studies (M. tuberculosis) National Microbial Pathogen Data Resource
  • yeastgenome Systematic deletion of yeast genes Saccharomyces Genome Database
  • goodall The Essential Genome of Escherichia coli K-12 (Transposon directed high-throughput mutagenesis) Goodall, Emily CA, et al. "The essential genome of Escherichia coli K-12." mBio 9.1 (2018): e02096-17.
  • alsford High-throughput phenotyping using parallel sequencing of RNA interference targets in the African trypanosome Genome Res 2011, 21:915-924
  • sidik A Genome-wide CRISPR Screen in Toxoplasma Identifies Essential Apicomplexan Genes. Sidik, Saima M., et al. "A genome-wide CRISPR screen in toxoplasma identifies essential apicomplexan genes." Cell 166.6 (2016): 1423-1435.

Phenotypes and Validation (curated)

Annotated phenotypes:

Affected Entity Phenotypic quality Occurs in Occurs at Evidence Observed in Drugs/Inhibitors
growth (GO:0040007) decreased time (PATO:0000716) single cell organism (CARO:0000064) amastigote (BTO:0000062) inferred from bioassay (ECO:0000094) Leishmania mexicana 337527   561727   585910  
Annotator: aaronjr@u.washington.edu. Comment: Drug: 4174-73-6. chemical inhibition with known cysteine peptidase inhibitors leads to slow growth of Leishmania sp. in cell assay; General cysteine peptidase inhibition with anti-leishmanial activity; specific target unknown. References: 7179420
growth (GO:0040007) decreased time (PATO:0000716) single cell organism (CARO:0000064) promastigote (BTO:0001124) inferred from bioassay (ECO:0000094) Leishmania mexicana 337527   561727   585910  
Annotator: aaronjr@u.washington.edu. Comment: Drug: 4174-73-6. chemical inhibition with known cysteine peptidase inhibitors leads to slow growth of Leishmania sp. in cell assay; General cysteine peptidase inhibition with anti-leishmanial activity; specific target unknown. References: 7179420
catalytic activity (GO:0003824) decreased (PATO:0000468) in vitro (MI:0492) inferred from enzyme assay (ECO:0000005) Leishmania mexicana 337527   561727   585910  
Annotator: aaronjr@u.washington.edu. Comment: Drug: 4174-73-6. chemical inhibition with known cysteine peptidase inhibitors leads to reduced enzyme activity in vitro; General cysteine peptidase inhibition with anti-leishmanial activity; specific target unknown. References: 7179420
growth (GO:0040007) decreased time (PATO:0000716) single cell organism (CARO:0000064) amastigote (BTO:0000062) inferred from bioassay (ECO:0000094) Leishmania amazonensis No drug identifiers listed for this gene.
Annotator: aaronjr@u.washington.edu. Comment: L-Amino acid esters appear to be hydrolyzed by cysteine peptidase and lead to slow growth of Leishmania sp. in cell assay; . References: 1428504 2235078 2345655
growth (GO:0040007) decreased time (PATO:0000716) single cell organism (CARO:0000064) amastigote (BTO:0000062) inferred from bioassay (ECO:0000094) Leishmania mexicana No drug identifiers listed for this gene.
Annotator: aaronjr@u.washington.edu. Comment: chemical inhibition with known cysteine peptidase inhibitors leads to slow growth of Leishmania sp. in cell assay; . References: 2270108
catalytic activity (GO:0003824) decreased (PATO:0000468) in vitro (MI:0492) inferred from enzyme assay (ECO:0000005) Leishmania amazonensis 81384   576750  
Annotator: aaronjr@u.washington.edu. Comment: chemical inhibition with known cysteine peptidase inhibitors leads to reduced enzyme activity in vitro; General cysteine peptidase inhibition with anti-leishmanial activity; specific target unknown. References: 8023752
catalytic activity (GO:0003824) decreased (PATO:0000468) in vitro (MI:0492) inferred from enzyme assay (ECO:0000005) Leishmania major 81384   576750  
Annotator: aaronjr@u.washington.edu. Comment: chemical inhibition with known cysteine peptidase inhibitors leads to reduced enzyme activity in vitro; General cysteine peptidase inhibition with anti-leishmanial activity; specific target unknown. References: 8023752
growth (GO:0040007) decreased time (PATO:0000716) single cell organism (CARO:0000064) amastigote (BTO:0000062) host (GO:0018995) Leishmania donovani No drug identifiers listed for this gene.
Annotator: aaronjr@u.washington.edu. Comment: Drug: 81989-95-9. chemical inhibition with known cysteine peptidase inhibitors leads to slow growth of Leishmania sp. in vivo (balb/c mouse) and cure of parasite burden; also provided protection against further infection (partial vaccine); General cysteine peptidase inhibition with anti-leishmanial activity; specific target unknown. References: 11238649
growth (GO:0040007) decreased time (PATO:0000716) single cell organism (CARO:0000064) amastigote (BTO:0000062) inferred from bioassay (ECO:0000094) Leishmania donovani No drug identifiers listed for this gene.
Annotator: aaronjr@u.washington.edu. Comment: Drug: 81989-95-9. chemical inhibition with known cysteine peptidase inhibitors leads to slow growth of Leishmania sp. in vivo (balb/c mouse) and cure of parasite burden; also provided protection against further infection (partial vaccine); General cysteine peptidase inhibition with anti-leishmanial activity; specific target unknown. References: 11238649
growth (GO:0040007) decreased time (PATO:0000716) single cell organism (CARO:0000064) amastigote (BTO:0000062) host (GO:0018995) Leishmania tropica No drug identifiers listed for this gene.
Annotator: aaronjr@u.washington.edu. Comment: Drug: 233277-99-1. chemical inhibition with known cysteine peptidase inhibitors leads to slow growth of Leishmania sp. in vivo (balb/c mouse lesions) and reduced lesion size; General cysteine peptidase inhibition with anti-leishmanial activity; specific target unknown. References: 15172223
growth (GO:0040007) decreased time (PATO:0000716) single cell organism (CARO:0000064) amastigote (BTO:0000062) inferred from bioassay (ECO:0000094) Leishmania tropica No drug identifiers listed for this gene.
Annotator: aaronjr@u.washington.edu. Comment: Drug: 233277-99-1. chemical inhibition with known cysteine peptidase inhibitors leads to slow growth of Leishmania sp. in vivo (balb/c mouse lesions) and reduced lesion size; General cysteine peptidase inhibition with anti-leishmanial activity; specific target unknown. References: 15172223
growth (GO:0040007) decreased time (PATO:0000716) single cell organism (CARO:0000064) promastigote (BTO:0001124) inferred from bioassay (ECO:0000094) Leishmania tropica No drug identifiers listed for this gene.
Annotator: aaronjr@u.washington.edu. Comment: Drug: 233277-99-1. chemical inhibition with known cysteine peptidase inhibitors leads to slow growth of Leishmania sp. in cell assay; inhibitors overcome redundancy?; General cysteine peptidase inhibition with anti-leishmanial activity; specific target unknown. References: 15172223
growth (GO:0040007) decreased time (PATO:0000716) single cell organism (CARO:0000064) promastigote (BTO:0001124) inferred from bioassay (ECO:0000094) Leishmania donovani 0   6693   81384   236103   327961   376038   543486   543487   575389   575390   575391   576750  
Annotator: aaronjr@u.washington.edu. Comment: Drug: 22386-37-4; Drug: 36677-78-8; Drug: 52090-11-6; Drug: 98319-30-3; Drug: 300670-24-0; Drug: 302939-54-4; Drug: 303216-44-6; Drug: 309742-24-3; Drug: 312280-89-0; Drug: 315703-20-9; Drug: 320369-30-0; Drug: 322409-94-9; Drug: 330220-86-5; Drug: 335206-77-4; Drug: 347910-28-5; Drug: 352560-86-2; Drug: 363180-61-4; Drug: 413580-11-7; Drug: 416878-80-3; Drug: 419547-26-5; Drug: 428852-79-3; Drug: 825612-08-6; Drug: 825612-09-7; Drug: 825612-10-0. in silico virtual screening of falcipains lead to bioactive compounds against Leishmania promastigotes; General cysteine peptidase inhibition with anti-leishmanial activity; specific target unknown. References: 15588096
catalytic activity (GO:0003824) decreased (PATO:0000468) in vitro (MI:0492) inferred from in-silico analysis (ECO:0000043) Leishmania donovani 0   6693   81384   236103   327961   376038   543486   543487   575389   575390   575391   576750  
Annotator: aaronjr@u.washington.edu. Comment: Drug: 22386-37-4; Drug: 36677-78-8; Drug: 52090-11-6; Drug: 98319-30-3; Drug: 300670-24-0; Drug: 302939-54-4; Drug: 303216-44-6; Drug: 309742-24-3; Drug: 312280-89-0; Drug: 315703-20-9; Drug: 320369-30-0; Drug: 322409-94-9; Drug: 330220-86-5; Drug: 335206-77-4; Drug: 347910-28-5; Drug: 352560-86-2; Drug: 363180-61-4; Drug: 413580-11-7; Drug: 416878-80-3; Drug: 419547-26-5; Drug: 428852-79-3; Drug: 825612-08-6; Drug: 825612-09-7; Drug: 825612-10-0. in silico virtual screening of falcipains lead to bioactive compounds against cysteine protease in vitro; General cysteine peptidase inhibition with anti-leishmanial activity; specific target unknown. References: 15588096
catalytic activity (GO:0003824) decreased (PATO:0000468) in vitro (MI:0492) inferred from specific protein inhibition (ECO:0000020) Leishmania donovani 0   6693   81384   236103   327961   376038   543486   543487   575389   575390   575391   576750  
Annotator: aaronjr@u.washington.edu. Comment: Drug: 22386-37-4; Drug: 36677-78-8; Drug: 52090-11-6; Drug: 98319-30-3; Drug: 300670-24-0; Drug: 302939-54-4; Drug: 303216-44-6; Drug: 309742-24-3; Drug: 312280-89-0; Drug: 315703-20-9; Drug: 320369-30-0; Drug: 322409-94-9; Drug: 330220-86-5; Drug: 335206-77-4; Drug: 347910-28-5; Drug: 352560-86-2; Drug: 363180-61-4; Drug: 413580-11-7; Drug: 416878-80-3; Drug: 419547-26-5; Drug: 428852-79-3; Drug: 825612-08-6; Drug: 825612-09-7; Drug: 825612-10-0. in silico virtual screening of falcipains lead to bioactive compounds against cysteine protease in vitro; General cysteine peptidase inhibition with anti-leishmanial activity; specific target unknown. References: 15588096
growth (GO:0040007) decreased time (PATO:0000716) single cell organism (CARO:0000064) promastigote (BTO:0001124) inferred from bioassay (ECO:0000094) Leishmania donovani No drug identifiers listed for this gene.
Annotator: aaronjr@u.washington.edu. Comment: Drug: 2935-91-3; Drug: 24117-97-3; Drug: 98647-23-5; Drug: 198124-18-4; Drug: 256238-87-6; Drug: 257287-52-8; Drug: 263157-80-8; Drug: 294854-43-6; Drug: 303124-84-7; Drug: 303147-38-8; Drug: 321579-84-4; Drug: 331247-87-1; Drug: 337923-53-2; Drug: 338791-39-2; Drug: 675828-74-7; Drug: 676226-56-5; Drug: 678967-57-2; Drug: 681213-40-1; Drug: 686272-33-3; Drug: 696586-43-3; Drug: 705250-31-3; Drug: 708987-83-1; Drug: 831234-40-3; Drug: 882161-95-7; Drug: 882161-98-0; Drug: 882161-99-1; Drug: 882162-00-7; Drug: 882162-01-8; Drug: 882162-02-9; Drug: 882162-03-0; Drug: 882162-04-1; Drug: 882162-05-2; Drug: 882162-06-3; Drug: 882162-07-4; Drug: 882162-08-5; Drug: 882162-09-6; Drug: 882162-10-9; Drug: 882162-11-0; Drug: 882162-12-1; Drug: 882162-13-2; Drug: 882162-14-3. in silico virtual screening of falcipains lead to bioactive compounds against Leishmania promastigotes; General cysteine peptidase inhibition with anti-leishmanial activity; specific target unknown. References: 16509575
catalytic activity (GO:0003824) decreased (PATO:0000468) in vitro (MI:0492) inferred from in-silico analysis (ECO:0000043) Leishmania donovani No drug identifiers listed for this gene.
Annotator: aaronjr@u.washington.edu. Comment: Drug: 2935-91-3; Drug: 24117-97-3; Drug: 98647-23-5; Drug: 198124-18-4; Drug: 256238-87-6; Drug: 257287-52-8; Drug: 263157-80-8; Drug: 294854-43-6; Drug: 303124-84-7; Drug: 303147-38-8; Drug: 321579-84-4; Drug: 331247-87-1; Drug: 337923-53-2; Drug: 338791-39-2; Drug: 675828-74-7; Drug: 676226-56-5; Drug: 678967-57-2; Drug: 681213-40-1; Drug: 686272-33-3; Drug: 696586-43-3; Drug: 705250-31-3; Drug: 708987-83-1; Drug: 831234-40-3; Drug: 882161-95-7; Drug: 882161-98-0; Drug: 882161-99-1; Drug: 882162-00-7; Drug: 882162-01-8; Drug: 882162-02-9; Drug: 882162-03-0; Drug: 882162-04-1; Drug: 882162-05-2; Drug: 882162-06-3; Drug: 882162-07-4; Drug: 882162-08-5; Drug: 882162-09-6; Drug: 882162-10-9; Drug: 882162-11-0; Drug: 882162-12-1; Drug: 882162-13-2; Drug: 882162-14-3. in silico virtual screening of falcipains lead to bioactive compounds against cysteine protease in vitro; General cysteine peptidase inhibition with anti-leishmanial activity; specific target unknown. References: 16509575
catalytic activity (GO:0003824) decreased (PATO:0000468) in vitro (MI:0492) inferred from specific protein inhibition (ECO:0000020) Leishmania donovani No drug identifiers listed for this gene.
Annotator: aaronjr@u.washington.edu. Comment: Drug: 2935-91-3; Drug: 24117-97-3; Drug: 98647-23-5; Drug: 198124-18-4; Drug: 256238-87-6; Drug: 257287-52-8; Drug: 263157-80-8; Drug: 294854-43-6; Drug: 303124-84-7; Drug: 303147-38-8; Drug: 321579-84-4; Drug: 331247-87-1; Drug: 337923-53-2; Drug: 338791-39-2; Drug: 675828-74-7; Drug: 676226-56-5; Drug: 678967-57-2; Drug: 681213-40-1; Drug: 686272-33-3; Drug: 696586-43-3; Drug: 705250-31-3; Drug: 708987-83-1; Drug: 831234-40-3; Drug: 882161-95-7; Drug: 882161-98-0; Drug: 882161-99-1; Drug: 882162-00-7; Drug: 882162-01-8; Drug: 882162-02-9; Drug: 882162-03-0; Drug: 882162-04-1; Drug: 882162-05-2; Drug: 882162-06-3; Drug: 882162-07-4; Drug: 882162-08-5; Drug: 882162-09-6; Drug: 882162-10-9; Drug: 882162-11-0; Drug: 882162-12-1; Drug: 882162-13-2; Drug: 882162-14-3. in silico virtual screening of falcipains lead to bioactive compounds against cysteine protease in vitro; General cysteine peptidase inhibition with anti-leishmanial activity; specific target unknown. References: 16509575
growth (GO:0040007) decreased time (PATO:0000716) single cell organism (CARO:0000064) promastigote (BTO:0001124) inferred from bioassay (ECO:0000094) Leishmania major No drug identifiers listed for this gene.
Annotator: aaronjr@u.washington.edu. Comment: Drug: 872361-01-8; Drug: 872361-02-9; Drug: 886061-72-9; Drug: 886061-73-0; Drug: 886061-74-1; Drug: 886061-75-2; Drug: 886061-76-3; Drug: 886061-77-4; Drug: 886061-78-5; Drug: 886061-79-6; Drug: 886061-80-9; Drug: 886061-81-0; Drug: 886061-82-1; Drug: 886061-85-4; Drug: 886061-86-5; Drug: 886061-87-6; Drug: 886061-88-7; Drug: 886061-89-8; Drug: 886061-90-1; Drug: 886061-91-2; Drug: 886061-92-3; Drug: 886061-93-4; Drug: 886061-99-0; Drug: 886062-00-6; Drug: 886062-05-1; Drug: 886062-06-2; Drug: 886062-07-3; Drug: 886062-08-4; Drug: 886062-09-5; Drug: 886062-10-8; Drug: 886062-11-9; Drug: 886062-12-0; Drug: 886062-13-1; Drug: 886062-14-2; Drug: 886062-15-3; Drug: 886062-16-4; Drug: 886062-17-5; Drug: 906674-95-1. chemical inhibition with peptidomimetics and Aziridine-2,3-dicarboxylates leads to slow growth of Leishmania sp. in cell assay; General cysteine peptidase inhibition with anti-leishmanial activity; specific target unknown. References: 16801424

In TDR Targets, information about phenotypes that are caused by drugs, or by genetic manipulation of cells (e.g. gene knockouts or knockdowns) is manually curated from the literature. These descriptions help to describe the potential of the target for drug development. If no information is available for this gene or if the information is incomplete, this may mean that i) the papers containing this information either appeared after the curation effort for this organism was carried out or they were inadvertently missed by curators; or that ii) the curation effort for this organism has not yet started.

In any case, if you have information about papers containing relevant validation data for this target, please contact us.

Annotated validation

  • Validation: in vivo inhibition
  • annotated by: aaronjr@u.washington.edu.
  • References: 11238649 15172223

Associated compounds / Druggability

Known modulators for this target

Compound Source Reference
Curated by TDRTargets References
Curated by TDRTargets References
Curated by TDRTargets References
Curated by TDRTargets References
Curated by TDRTargets References
Curated by TDRTargets References
Curated by TDRTargets References
Curated by TDRTargets References
Curated by TDRTargets References
Curated by TDRTargets References
Curated by TDRTargets References
Curated by TDRTargets References
Curated by TDRTargets References
Curated by TDRTargets References

Predicted associations

By orthology with druggable targets
Non orthologous druggable targets
By sequence similarity to non orthologous druggable targets
No additional associated druggable targets
Obtained from network model
No druggable targets predicted through repurposing network model

Assayability

Assay information

No assay information for this target.

Reagent availability

No reagent availability information for this target.

Bibliographic References

11 literature references were collected for this gene.

If you have references for this gene, please enter them in a user comment (below) or Contact us.

User comments

No user comments are available for this gene. Log in to add comments, or register.

Enter your comment

User ()
Gene identifier LmjF.30.0250 (Leishmania major), ubiquitin hydrolase, putative,cysteine peptidase, Clan CA, family C19, putative
Title for this comment
Comment